抗骨解剂双酸金属药物协调网络:溶解概况和In Vitro/In Vivo毒性对控制释放的毒性
Elpiniki Chachlaki1, Maria Vassaki1, Petri A Turhanen2
1Crystal Engineering, Growth and Design Laboratory, Department of Chemistry, University of Crete, Heraklion Crete GR-71003, Greece.
ACS applied bio materials
|November 18, 2025
概括
新的配合化合物与土金属和骨寻找剂,如克洛德酸盐 (CLOD) 提供可控的药物释放. 这些生物相容化合物具有低毒性和可调节的释放率,提高了治疗潜力.
科学领域:
- 协调化学 协调化学
- 材料科学 材料科学 材料科学
- 生物医学工程 生物医学工程
背景情况:
- 寻找骨的药物,如克洛德罗纳酸 (CLOD) 和梅德罗纳酸 (MED),对于治疗骨疾病至关重要.
- 开发这些药物的可控释放系统对于优化治疗疗效和最小化副作用至关重要.
- 土金属离子 (Mg2+,Ca2+,Sr2+) 是生物相容的,可以纳入协调化合物中.
研究的目的:
- 通过使用生物相容的土金属离子和寻找骨的酸盐 (CLOD和MED) 合成和描述新的协调化合物.
- 在模拟胃的酸性条件下研究这些化合物中CLOD和MED的受控释放概况.
- 为了评估合成化合物的毒性.
主要方法:
- 具有不同维度 (0D,1D,2D) 的协调化合物的合成和结构特征.
- 从含有辅助剂的片剂中控制释放CLOD和MED的研究,pH值为1.3.
- 在体外 (微核测定) 和体内 (盐水) 毒性评估.
主要成果:
- 合成的Mg-CLOD,Ca-CLOD,Ca-CLOD-CP,Ca-MED和Sr-CLOD化合物具有不同的结构维度.
- 所有含有Mg/Ca/Sr的化合物与参考盐相比,CLOD的释放速度减慢,在Na> Mg> Sr> Ca之后,最初的释放率为Na> Mg> Sr> Ca.
- MED和Ca-MED系统也显示出受控释放,所有测试的化合物都表现出低毒性.
结论:
- 带有CLOD和MED的土金属的协调化合物为骨寻找剂提供了有效的控制释放系统.
- 结构因素,如金属-联体结合,H结合和晶体包装影响药物释放动力学.
- 合成的化合物是生物相容的,具有低毒性,表明它们在制药应用中的潜力.
相关概念视频
Bioavailability Enhancement: Drug Stability Enhancement and GI Retention
185
Body:Improving a drug's stability in the gastrointestinal (GI) tract is paramount for enhancing its bioavailability and therapeutic effectiveness. Various strategies are employed to protect the drug from the harsh gastric milieu and to ensure its release and absorption at the desired site within the GI tract.Polymer coatings are one such method used to shield drugs from the stomach's acidic environment. By preventing premature drug release, these coatings improve the bioavailability of unstable...
185
Drug Distribution: Tissue Binding
3.8K
Upon entering the systemic circulation, drugs can distribute into the interstitial and intracellular fluid of various tissue cells. This distribution is facilitated by the binding of drugs to different cellular components within tissues, which may lead to drug accumulation in specific areas. Drugs bound to tissue components serve as reservoirs that release free drugs back into the system, prolonging the drug's overall action. However, this accumulation can also result in local toxicity.
For...
For...
3.8K
Factors Affecting Dissolution: Drug Permeability, Stability and Stereochemistry
481
Orally administered drugs primarily enter the systemic circulation via passive diffusion through the intestinal membranes. The drug's absorption is influenced by drug stability in the gastrointestinal GI tract, membrane permeability, the surface area available for absorption, luminal drug concentration, and residence time in the lumen. Drug permeability can be enhanced by adjusting the lipophilicity, polarity, or molecular size of the drug, promoting its passive transport across intestinal...
481
Pharmaceutical Alternatives: Polymorphic Form-Related and Particle Size-Related Therapeutic Nonequivalence
139
Changes in polymorphic forms can significantly influence the bioavailability of poorly soluble drugs. Although the FDA defines pharmaceutical equivalence based on having the same active ingredient, dosage form, and route of administration, it does not automatically disqualify products with different polymorphic forms. This means two products with different polymorphs can still be deemed pharmaceutically equivalent. However, polymorphic differences can affect properties like wettability,...
139
Osteoclasts in Bone Remodeling
3.8K
Osteoclasts are cells responsible for bone resorption and remodeling. They originate from hematopoietic progenitor cells present in the bone marrow. Numerous progenitor cells fuse to form multinucleated cells, each with 10-20 nuclei. A single osteoclast has a diameter of 150 to 200 µM. These cells have ruffled borders that break down the underlying bone tissue and release minerals such as calcium into the blood in bone resorption. Osteoclasts cling to bones with their ruffled edges during...
3.8K
Factors Affecting Dissolution: Polymorphism, Amorphism and Pseudopolymorphism
648
Polymorphism refers to the existence of a drug substance in multiple crystalline forms, known as polymorphs. Recently, this term has been expanded to include solvates (forms containing a solvent), amorphous forms (non-crystalline forms), and desolvated solvates (forms from which the solvent has been removed).
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
Some polymorphic crystals possess lower aqueous solubility than their amorphous counterparts, leading to incomplete absorption. For instance, the oral suspension of Chloramphenicol, which...
648


